Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Ethacridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.85 |
| ▸ | BLM | P54132 | 2/20 | 0.85 |
| ▸ | TERT | O14746 | 1/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | THRB | P10828 | 1/20 | 0.85 |
| ▸ | CASP7 | P55210 | 3/20 | 0.77 |
| ▸ | CASP1 | P29466 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethacridine SCHEMBL30310148 | 0.92 | MEN1 (1.00) | MEN1KMT2ABLMTERTABCB11 | |
| Ethacridine SCHEMBL11662539 | 0.92 | MEN1 (1.00) | MEN1KMT2ABLMTERTABCB11 | |
| Ethacridine SCHEMBL193949 | 0.92 | MEN1 (1.00) | MEN1KMT2ABLMTERTABCB11 | |
| Ethacridine SCHEMBL29456272 | 0.92 | MEN1 (1.00) | MEN1KMT2ABLMTERTABCB11 | |
| Ethacridine SCHEMBL30753462 | 0.91 | MEN1 (0.97) | MEN1KMT2ABLMTERTABCB11 | |
| Ethacridine SCHEMBL9355974 | 0.91 | MEN1 (0.97) | MEN1KMT2ABLMTERTABCB11 | |
| Ethacridine SCHEMBL31197660 | 0.87 | MEN1 (1.00) | MEN1KMT2ABLMTERTABCB11 | |
| Ethacridine SCHEMBL30006678 | 0.87 | MEN1 (1.00) | MEN1KMT2ABLMTERTABCB11 | |
| Ethacridine SCHEMBL30775016 | 0.87 | MEN1 (1.00) | MEN1KMT2ABLMTERTABCB11 | |
| Ethacridine SCHEMBL138154 | 0.87 | MEN1 (1.00) | MEN1KMT2ABLMTERTABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092684-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | ANTIBODY SYSTEMS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | ANTIBODY SYSTEMS, INC. | 2002-06-20 | — | — | US | disclosed |
| EP-1171163-A1 | COMPOSITIONS CONTAINING TETRACYCLINES FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS | Antibody Systems, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000064479-A1 | COMPOSITIONS CONTAINING TETRACYCLINES FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS | ANTIBODY SYSTEMS, INC. (US) | 2000-11-02 | — | — | WO | disclosed |
| EP-0440561-A1 | Process for the extraction and/or selective prepurification of proteins contained in dairy products | ASSOCIATION POUR LA RECHERCHE ET LE DEVELOPPEMENT DES METHODES ET PROCESSUS INDUSTRIELS (ARMINES) (FR) | 1991-08-07 | — | — | EP | disclosed |
| EP-0035204-B2 | PASTEURIZED THERAPEUTICALLY ACTIVE PROTEIN COMPOSITIONS | MILES INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0035204-A2 | Pasteurized therapeutically active protein compositions | MILES INC. (US) | 1981-09-09 | — | — | EP | disclosed |
| US-4154819-A | Preparation of a gamma-globulin solution suitable for intravenous administration using diketene | BIOTEST-SERUM-INSTITUT GMBH (DE) | 1979-05-15 | — | — | US | disclosed |
| US-4082734-A | HEATING AND FRACTIONATING HUMAN SERUM | BIOTEST-SERUM-INSTITUT GMBH (DT) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | IL1R1, TNF, IL1A | MEN1 2311/4885KMT2A 3996/4885BLM 1718/4885 |
| US-20030092684-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | CCL11, SSB, TNF | MEN1 2687/4885KMT2A 3218/4885BLM 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.